Literature DB >> 22381138

Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata.

Tetsuro Yahata1, Chiaki Banzai, Kenichi Tanaka.   

Abstract

AIM: The histology-specific long-term trends in the incidence of ovarian cancer and borderline tumors in Japanese women were examined, based on data from the population-based cancer registry in Niigata, Japan.
MATERIAL AND METHODS: Data were obtained from the Niigata Gynecological Cancer Registry, which covered the entire female population in Niigata prefecture, Japan, during the period from 1983 to 2007.
RESULTS: A total of 3134 females with epithelial ovarian cancer, including borderline tumor cases, were diagnosed between 1983 and 2007. The age-standardized rates (ASRs) of both ovarian cancer and borderline tumors have steadily increased, with significant changes in ovarian cancer in all age groups, and borderline ovarian tumors in subjects aged <50. The ASRs of endometrioid adenocarcinoma showed a steady increasing trend, and those of clear cell and mucinous adenocarcinomas showed significant increasing trends in the total population. The ASRs of clear cell, mucinous, and endometrioid adenocarcinomas in the 50+ age group were significantly increased, especially the incidence of clear cell adenocarcinoma, which strikingly increased by approximately threefold from 1.2 (1983-1989) to 3.5 (2000-2007) per 100,000 females.
CONCLUSION: This prefecture-wide study showed the practical trends in ovarian cancer and borderline tumors in Japanese females. The incidence of ovarian cancer has steadily increased, with significant increases in the incidence of clear cell and mucinous adenocarcinomas in the total population during the past two decades. Because of the poor response rate of these histological subtypes to platinum-based regimens, novel treatment approaches should be adopted to improve the prognostic outcome in patients with ovarian cancer in Japan.
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2012        PMID: 22381138     DOI: 10.1111/j.1447-0756.2011.01755.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  10 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

2.  A retrospective analysis of relapse-related factors for ovarian borderline tumors.

Authors:  Dan Ye; Haoran Shen; Wu Huang; Liangqing Yao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

3.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22

4.  An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Authors:  Kate E Oliver; William E Brady; Michael Birrer; David M Gershenson; Gini Fleming; Larry J Copeland; Krishnansu Tewari; Peter A Argenta; Robert S Mannel; Angeles Alvarez Secord; Jean-Marie Stephan; David G Mutch; Frederick B Stehman; Franco M Muggia; Peter G Rose; Deborah K Armstrong; Michael A Bookman; Robert A Burger; John H Farley
Journal:  Gynecol Oncol       Date:  2017-08-12       Impact factor: 5.482

5.  Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Authors:  Aikou Okamoto; Jalid Sehouli; Nozomu Yanaihara; Yukihiro Hirata; Ioana Braicu; Byoung-Gie Kim; Satoshi Takakura; Misato Saito; Satoshi Yanagida; Masataka Takenaka; Noriko Yamaguchi; Asuka Morikawa; Hiroshi Tanabe; Kyosuke Yamada; Kosuke Yoshihara; Takayuki Enomoto; Hiroaki Itamochi; Junzo Kigawa; Noriomi Matsumura; Ikuo Konishi; Satoshi Aida; Yuko Aoki; Nobuya Ishii; Kazunori Ochiai; Tetsu Akiyama; Mitsuyoshi Urashima
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.

Authors:  Erika Nakatsuka; Kenjiro Sawada; Koji Nakamura; Akihito Yoshimura; Yasuto Kinose; Michiko Kodama; Kae Hashimoto; Seiji Mabuchi; Hiroshi Makino; Eiichi Morii; Yoichi Yamaguchi; Takeshi Yanase; Akiko Itai; Ken-Ichirou Morishige; Tadashi Kimura
Journal:  Oncotarget       Date:  2017-09-12

7.  Ovarian Cancer Incidence in the Multi-Ethnic Asian City-State of Singapore 1968-2012.

Authors:  Jeff Yi-Fu Hwang; Wei-Yen Lim; Chuen Seng Tan; Sheow Lei Lim; John Chia; Khuan Yew Chow; Wen Yee Chay
Journal:  Asian Pac J Cancer Prev       Date:  2019-12-01

8.  Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.

Authors:  Yung-Taek Ouh; Dongwoo Kang; Hoseob Kim; Jae Kwan Lee; Jin Hwa Hong
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

9.  Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review.

Authors:  Morikazu Miyamoto; Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

Review 10.  Application of microRNA in diagnosis and treatment of ovarian cancer.

Authors:  Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kanako Nakamura; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Hiroyuki Nomura; Fumio Kataoka; Eiichiro Tominaga; Daisuke Aoki
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.